These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20961501)

  • 1. [Glucagon-like peptide-1: a cardiological perspective].
    Elvekjaer M; Engstrøm T; Jensen JS; Treiman M
    Ugeskr Laeger; 2010 Oct; 172(41):2822-6. PubMed ID: 20961501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiac effects of glucagon-like peptide 1].
    Holst JJ
    Ugeskr Laeger; 2010 Oct; 172(41):2821. PubMed ID: 20961500
    [No Abstract]   [Full Text] [Related]  

  • 3. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
    Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 agonists.
    Padwal R
    BMJ; 2012 Jan; 344():d7282. PubMed ID: 22236410
    [No Abstract]   [Full Text] [Related]  

  • 6. Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease.
    Lebovitz HE; Banerji MA
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S43-50. PubMed ID: 22650224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin concepts.
    Bloomgarden ZT
    Diabetes Care; 2010 Feb; 33(2):e20-5. PubMed ID: 20103551
    [No Abstract]   [Full Text] [Related]  

  • 8. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
    Consoli A; Di Biagio R
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
    Haluzík M; Trachta P; Mráz M
    Vnitr Lek; 2015; 61(7-8):635-40. PubMed ID: 26375689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
    Beiroa D; Imbernon M; Gallego R; Senra A; Herranz D; Villarroya F; Serrano M; Fernø J; Salvador J; Escalada J; Dieguez C; Lopez M; Frühbeck G; Nogueiras R
    Diabetes; 2014 Oct; 63(10):3346-58. PubMed ID: 24917578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function.
    Saraceni C; Broderick TL
    Drugs R D; 2007; 8(3):145-53. PubMed ID: 17472410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of glucagonlike peptide-1 agonists.
    Davidson MH
    Am J Cardiol; 2011 Aug; 108(3 Suppl):33B-41B. PubMed ID: 21802579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
    Ban K; Kim KH; Cho CK; Sauvé M; Diamandis EP; Backx PH; Drucker DJ; Husain M
    Endocrinology; 2010 Apr; 151(4):1520-31. PubMed ID: 20172966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 18. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
    Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
    Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 receptor agonist effects on normal and neoplastic pancreata.
    Goggins M
    Diabetes; 2012 May; 61(5):989-90. PubMed ID: 22517654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.